Source comparison
Clinical Evidence and Research Outcomes for DSIP vs Sermorelin
DSIP's evidence base originates primarily from Eastern European and Russian research conducted in the 1970s and 1980s, with limited replication in Western clinical trials. The original studies. Published in journals like Peptides and the European Journal of Ph
This comparison does not assign a generated winner or score.
- DSIP's evidence base originates primarily from Eastern European and Russian research conducted in the 1970s and 1980s, with limited replication in Western clinical trials. The original studies. Published in journals like Peptides and the European Journal of Pharmacology. Demonstrated sleep latency reductions of 15–20 minutes and increases in slow-wave sleep percentage from baseline 18–22% to 28–31% of total sleep time. These results were dose-dependent, with protocols using 25–100 mcg administered intranasally or subcutaneously 30–60 minutes before sleep onset. More recent work has been sparse, and the peptide remains largely unstudied in large-scale randomized controlled trials, which limits definitive claims about efficacy magnitude.
- Sermorelin has a more robust modern evidence base, particularly in studies examining growth hormone deficiency and age-related GH decline. A 2012 study published in the Journal of Clinical Endocrinology & Metabolism found that Sermorelin dosed at 100 mcg daily for 16 weeks increased serum IGF-1 levels by 35–42% from baseline in adults with documented GH insufficiency. Body composition studies using DEXA scanning reported lean mass increases of 1.2–1.8 kg and fat mass reductions of 0.9–1.4 kg over the same period. Importantly, these effects were sustained only during active dosing. Discontinuation led to gradual regression toward baseline within 8–12 weeks, consistent with the peptide's lack of receptor desensitization but dependence on continuous stimulation.
- The comparison becomes clearer when framed correctly: DSIP's outcomes are measured in polysomnography metrics (sleep stage percentages, delta power density, sleep efficiency), while Sermorelin's outcomes are measured in endocrine markers (serum GH, IGF-1, body composition changes). One does not substitute for the other. Researchers evaluating sleep architecture improvements should not expect Sermorelin to deliver those results, and those studying anabolic or metabolic endpoints should not expect DSIP to drive them.